文献速递前列腺癌肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

泌尿生殖系统肿瘤中淋巴结清扫的当代作用:2023年的现状

Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
PubMed 文献 · Eur Urol Oncol · 2023-11-18

本文是一篇协作性综述,总结泌尿上皮癌、前列腺癌、肾癌、阴茎癌和睾丸癌中淋巴结清扫的当代证据,讨论患者选择与推荐清扫模板,并指出知识空白和正在研究的领域。淋巴结清扫仍是淋巴结分期的参考标准,病理淋巴结分期影响预后并指导辅助治疗,合适的模板和患者选择对优化结局至关重要。

要点

  • 淋巴结清扫仍是泌尿生殖系统肿瘤淋巴结分期的参考标准。
  • 病理淋巴结分期可提供预后信息并指导辅助治疗。
  • 合适的清扫模板和患者选择对优化结局和发挥选择性治疗获益至关重要。

核心结论

  • 准确的淋巴结清扫分期取决于合适的模板选择,累积获益将取决于审慎的患者选择。

研究设计与样本

  • 本文为协作性综述,由泌尿外科多领域专家共同完成,总结泌尿上皮癌、前列腺癌、肾癌、阴茎癌和睾丸癌中淋巴结清扫的当前证据。

主要发现

  • 淋巴结清扫仍是淋巴结分期的参考标准,病理淋巴结分期影响预后并指导辅助治疗。
  • 合适的模板和患者选择对优化结局和发挥选择性治疗获益至关重要。
  • 综述指出了知识空白和正在研究的领域。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Lymphadenectomy during surgery for genitourinary malignancies has varying benefits. OBJECTIVE: To review contemporary evidence on lymph node dissection in genitourinary cancers. EVIDENCE ACQUISITION: We performed a collaborative review to summarize current evidence supporting lymph node dissection in urothelial, prostate, kidney, penile, and testis cancers. We present the evidence on patient selection and recommended dissection templates, and highlight knowledge gaps and ongoing areas of investigation. EVIDENCE SYNTHESIS: Lymph node dissection remains the reference standard for lymph node staging. Pathologic nodal stage informs prognosis and guides adjuvant treatment. Appropriate template and patient selection are paramount to optimize outcomes and capitalize on the selective therapeutic benefits. CONCLUSIONS: Accurate staging with lymphadenectomy is contingent on appropriate template selection. The cumulative benefit will depend on judicious patient selection. PATIENT SUMMARY: We performed a collaborative review by a diverse group of experts in urology. We reviewed current evidence on lymph node dissection.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Myers AA, Briganti A, Leibovich B, et al. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? Eur Urol Oncol. 2023. PMID: 37980250. doi:10.1016/j.euo.2023.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。